The role of radical prostatectomy (RP) or radiotherapy (RT) in intermediate-risk prostate cancer (PCa) is still under debate. Our aim was to quantify the effect of RP and RT on the average years of life lost (YLL) in patients with intermediate-risk PCa. Within the SEER database 2004–2021, intermediate-risk PCa patients...
F. Falkenbach, Mattia Longoni, A. Marmiroli et al.· World journal of urology· 0 citations
Population-based observations indicate that cryotherapy is associated with a higher risk of CSM compared with EBRT in these patients, and univariable competing risks regression models tested for CSM differences after accounting for other-cause mortality (OCM) as a competing event.
L. Quarta, M. Petix, M. Filzmayer et al.· World journal of urology· 0 citations
Muscle-invasive bladder cancer (MIBC) exhibits significant heterogeneity in clinical outcomes and treatment responses. While gene expression profiling has provided important biological and prognostic insight, transcriptomic assays are not routinely incorporated into standard clinical practice, in part due to cost. AI m...
I. F. Mathisen, F. Koll, R. Mayer et al.· Modern Pathology· 0 citations
PURPOSE
[177Lu]Lu-PSMA-617 is a standard-of-care therapy for metastatic castration-resistant prostate cancer (mCRPC). Given the heterogeneous clinical responses, accessible prognostic tools are needed. We recently demonstrated that the Bellmunt Risk Score (BRS)-comprising ECOG performance status >0, hemoglobin <10 g/dL...
T. Büttner, Mike Wenzel, Philipp Mandel et al.· European Journal of Nuclear...· 0 citations
Differences in tumor biology, ethnicities, and healthcare structures across populations may contribute to variability in oncologic outcomes. This study compared baseline characteristics and oncologic outcomes of Japanese and German metastatic hormone‐sensitive prostate cancer (mHSPC) patients.
Mike Wenzel, Keiichiro Miyajima, M. Filzmayer et al.· International journal of uro...· 2 citations
INTRODUCTION
Focal therapy (FT) in high-risk or very high-risk prostate cancer (CaP) is not guideline-recommended. However, it may be occasionally used, but its effect on cancer-specific mortality (CSM) relative to standard treatment options such as radical prostatectomy (RP) is unknown and was addressed in the present...
L. Quarta, M. Petix, M. Filzmayer et al.· Urologic oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.